Pancreatic Cancer Market Growth Projections 2024-2034: DelveInsight Analysis

The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.

DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pancreatic Cancer Market Forecast
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Pancreatic Cancer Market Report:
• The Pancreatic Cancer market size was valued approximately and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In November 2025, Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical firm with an extensive portfolio of drug candidates addressing hard-to-treat cancers and viral infections, announced that it has established a research and material transfer agreement with the University of North Carolina at Chapel Hill (UNC). This collaboration will support investigator-initiated preclinical studies assessing Annamycin for the treatment of pancreatic cancer.
• In September 2025, Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. (2563.HK), a synthetic biology-focused biopharma company developing innovative oncology therapies, announced that its lead pipeline candidate Utidelone has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pancreatic cancer. This represents the third ODD awarded to Utidelone, following previous FDA designations for breast cancer brain metastases and gastric cancer.
• In March 2025, Swedish immunotherapy firm Anocca has received regulatory clearance in four European countries to initiate its Phase I/II VIDAR-1 clinical trial. This study will focus on patients with advanced pancreatic cancer that is positive for the KRAS gene. The trial will start by assessing ANOC-001, Anocca's lead candidate, which specifically targets the KRAS G12V mutation, where glycine at position 12 is replaced by valine.
• In December 2024, Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control. The PANOVA-3 trial assessed the use of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
• According to DelveInsight's estimates, the total incident cases of pancreatic cancer in the United States accounted for approximately 35% in 2023.
• The 2023 analysis indicates that the highest stage-specific incident cases of pancreatic cancer in the US were for distant stages, comprising nearly 50% of cases, followed by regional and localized stages.
• The mutation types associated with pancreatic cancer include KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In the United States, KRAS2 and TP53 were responsible for the largest number of incident cases of pancreatic cancer in 2023.
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• The Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Pancreatic Cancer than females

Request a sample for the Pancreatic Cancer Market Report:
https://www.delveinsight.com/report-store/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Overview
Pancreatic cancer is a type of cancer that originates in the tissues of the pancreas, an organ located behind the stomach that plays a key role in digestion and blood sugar regulation. It often develops silently, showing few early symptoms, which makes it difficult to detect until advanced stages. Common signs may include abdominal pain, jaundice, weight loss, and digestive issues. Pancreatic cancer is aggressive, has a high mortality rate, and treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

Pancreatic Cancer Epidemiology Segmentation:
The Pancreatic Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Pancreatic Cancer
• Prevalent Cases of Pancreatic Cancer by severity
• Gender-specific Prevalence of Pancreatic Cancer
• Diagnosed Cases of Episodic and Chronic Pancreatic Cancer

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Epidemiological Insights
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Therapies and Key Companies
• LYNPARZA (olaparib): AstraZeneca
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Elraglusib (9 ING 41): Actuate Therapeutics
• DF 7001: Dragonfly Therapeutics CMG 901 Keymed B
• TNG260: Tango Therapeutics
• ATA 3271: Atara Biotherapeutics
• CMG 901: Keymed Biosciences Co.Ltd
• CT-0508: Carisma Therapeutics Inc
• CUE-102: Cue Biopharma
• BOLD-100: Bold Therapeutics
• CM24: Purple Biotech Ltd
• ENB-003: ENB Therapeutics
• GRT-C903: Gritstone bio
• AZD0171: AstraZeneca
• CAN-2409: Candel Therapeutics
• Mitazalimab: Alligator Bioscience
• Pamrevlumab: FibroGen
• NIS793: Novartis AG
• Masitinib: AB Science
• Glufosfamide: Eleison Pharmaceuticals

To know more about Pancreatic Cancer treatment, visit @ Pancreatic Cancer Medications
https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Cancer Market Drivers
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Pancreatic Cancer
• Strong pipeline activity

Pancreatic Cancer Market Barriers
• Rising incidence of cancer will provide a larger window of opportunity for new treatments
• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity

Scope of the Pancreatic Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics CMG 901 Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others
• Key Pancreatic Cancer Therapies: LYNPARZA (olaparib), KEYTRUDA (pembrolizumab), Elraglusib (9 ING 41), DF 7001, TNG260, ATA 3271, CMG 901, CT-0508, CUE-102, BOLD-100, CM24, ENB-003, GRT-C903, AZD0171, CAN-2409, Mitazalimab, Pamrevlumab, NIS793, Masitinib, Glufosfamide, and others
• Therapeutic Assessment: Pancreatic Cancer current marketed and Pancreatic Cancer emerging therapies
• Migraine Market Dynamics: Pancreatic Cancer market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Pancreatic Cancer Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.